Inactive Instrument

Acura Pharmaceuticals, Inc. Stock OTC Bulletin Board

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board
- ^USD	-

08-20	Acura Pharmaceuticals, Inc. Receives $200,000 Loan from Abuse Deterrent Pharma, Llc and Amends Secured Promissory Note	CI
07-25	Acura Pharmaceuticals, Inc. Receives $200,000 Loan From Abuse Deterrent Pharma, LLC	CI

Valuation : Acura Pharmaceuticals, Inc.

Market Cap	3.28M 2.82M 2.65M 2.42M 4.54M 310M 4.55M 31.37M 12.17M 159M 12.31M 12.04M 512M	P/E 2020	-5.25x	P/E 2021	-25x
Enterprise Value	3.41M 2.94M 2.76M 2.52M 4.72M 322M 4.74M 32.66M 12.67M 165M 12.82M 12.54M 533M	EV / Sales 2020	2.91x	EV / Sales 2021	20.9x
Free-Float	98.31%	Yield 2020 *	-	Yield 2021	-

* Estimated data More valuation ratios

Latest news : Acura Pharmaceuticals, Inc.

08-20	Acura Pharmaceuticals, Inc. Receives $200,000 Loan from Abuse Deterrent Pharma, Llc and Amends Secured Promissory Note	CI
07-25	Acura Pharmaceuticals, Inc. Receives $200,000 Loan From Abuse Deterrent Pharma, LLC	CI
06-24	Acura Pharmaceuticals, Inc. announced that it has received $0.2 million in funding	CI
05-29	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
03-11	Acura Pharmaceuticals, Inc. Receives Loans of $100,000 from Abuse Deterrent Pharma, LLC	CI
03-10	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
12-12	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
04/09/25	Acura Pharmaceuticals, Inc. Announces Loans from Abuse Deterrent Pharma, LLC	CI
03/09/25	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
18/07/25	Acura Pharmaceuticals, Inc. announced that it has received $8.394279 million in funding from Abuse Deterrent Pharma, LLC	CI
20/06/25	Acura Pharmaceuticals, Inc. announced that it has received $0.1 million in funding	CI
30/05/25	Acura Pharmaceuticals, Inc. Announces License, Development and Commercialization Agreement with AD Pharma	CI
30/05/25	Acura Pharmaceuticals, Inc. Amends Amend the November 10, 2022 Amended, Consolidated and Restated Secured Promissory Note with AD Pharma	CI

More news

Press Releases : Acura Pharmaceuticals, Inc.

16/12/24	Acura Pharmaceuticals : Financial Obligation Form 8 K	PU
26/07/24	Acura Pharmaceuticals : New Financial Obligation Form 8 K	PU
26/03/24	Acura Pharmaceuticals : TO LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT - Form 8-K	PU
21/12/23	Acura Pharmaceuticals : AMENDED, CONSOLIDATED AND RESTATED SECURED PROMISSORY NOTE - Form 8-K	PU
06/12/23	Acura Pharmaceuticals : New Financial Obligation - Form 8-K	PU

More press releases

Managers and Directors : Acura Pharmaceuticals, Inc.

Manager	Title	Age	Since
Robert Jones CEO	Chief Executive Officer	67	01/04/2011
Bob Seiser DFI	Director of Finance/CFO	62	01/08/2024
Albert Brzeczko CTO	Chief Tech/Sci/R&D Officer	69	01/02/2009

Director	Title	Age	Since
William Skelly CHM	Chairman	75	01/10/1996
Immanuel Thangaraj BRD	Director/Board Member	55	01/12/2002
Bruce Wesson BRD	Director/Board Member	83	01/03/1998

More insiders

Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-1.79%	-2.27%	+50.90%	+89.03%	69.02B
ARGENX SE	-2.06%	-0.18%	+41.53%	+88.17%	66.32B
INSMED INCORPORATED	-0.31%	+6.54%	-11.39%	+457.82%	27.66B
WUXI BIOLOGICS (CAYMAN) INC.	-3.00%	-2.90%	+39.40%	+9.41%	26.54B
BIONTECH SE	+0.86%	+1.65%	+0.25%	-14.78%	25.84B
GENMAB A/S	-1.46%	+0.42%	+24.07%	-18.70%	20.4B
PHARMAESSENTIA CORPORATION	-2.96%	-15.21%	+210.71%	+370.84%	17.63B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-1.49%	-4.88%	-0.41%	+530.26%	15.15B
EXELIXIS, INC.	-0.20%	+8.37%	+57.87%	+159.50%	14.65B
Average	-1.38%	-0.35%	+45.88%	+185.73%	31.47B
Weighted average by Cap.	-1.53%	-0.34%	+42.56%	+144.95%

	2020	2021
Net sales	3.57M 3.07M 2.89M 2.64M 4.94M 337M 4.95M 34.15M 13.25M 173M 13.41M 13.11M 557M	1.56M 1.34M 1.27M 1.16M 2.16M 148M 2.17M 14.95M 5.8M 75.71M 5.87M 5.74M 244M
Net income	-1.21M -1.04M -978K -893K -1.67M -114M -1.68M -11.56M -4.48M -58.52M -4.54M -4.44M -189M	-879K -756K -712K -650K -1.22M -82.99M -1.22M -8.41M -3.26M -42.58M -3.3M -3.23M -137M
Net Debt	5.86M 5.04M 4.74M 4.33M 8.1M 553M 8.12M 56.02M 21.74M 284M 21.99M 21.51M 914M	135K 116K 109K 99.84K 187K 12.75M 187K 1.29M 501K 6.54M 507K 496K 21.07M

Acura Pharmaceuticals, Inc. Stock OTC Bulletin Board

Stocks

Biotechnology & Medical Research

Valuation : Acura Pharmaceuticals, Inc.

Latest news : Acura Pharmaceuticals, Inc.

Press Releases : Acura Pharmaceuticals, Inc.

Managers and Directors : Acura Pharmaceuticals, Inc.

Bio Therapeutic Drugs

Financials

Company Profile